|Page (1) of 1 - 03/20/17||email article||print page|
(March 20, 2017)
BASEL, Switzerland, March 20, 2017 /PRNewswire/ -- Axovant Sciences (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced a change to the company's presentation time at the Oppenheimer 27th Annual Healthcare Conference.
Axovant will now present at 9:10 a.m. on Wednesday, March 22. A simultaneous webcast will be available for the conference in the Investors section of Axovant's website at www.axovant.com. A replay will be available for 30 days following the conference.
About Axovant Sciences
Axovant Sciences is a leading clinical-stage biopharmaceutical company focused on acquiring, developing and commercializing novel therapeutics for the treatment of dementia. Axovant intends to develop a pipeline of product candidates to comprehensively address the cognitive, functional and behavioral aspects of dementia and related neurological disorders. Our vision is to become the leading company focused on the treatment of dementia by addressing all forms and aspects of this condition.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/axovant-sciences-announces-presentation-time-change-at-oppenheimer-healthcare-conference-300426472.html
SOURCE Axovant Sciences
Copyright 2014 PR Newswire. All Rights Reserved
Related Sites: DMN Newswire , HTN - Health Technology Net
Related Newsletter: Tutorial Finder , Review Seeker , DMN Newswire Newsletter